Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
August 10 2020 - 4:22PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
|
SEC
FILE NUMBER
000-26372
|
FORM
12b –25
NOTIFICATION
OF LATE FILING
|
CUSIP
NUMBER
00547W208
|
Check
One:
☐
Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form
10-D ☐ Form N-CSR
For
Period Ended: June 30, 2020
☐
Transition
Report on Form 10-Q
☐
Transition
Report on Form 20-F
☐
Transition
Report on Form 11-K
☐
Transition
Report on Form 10-Q
☐
Transition
Report on Form N-SAR
For
the Transition Period Ended: __________________________
If
the notification relates to a portion of the filing check above, identify the Item(s) to which the notification relates:
PART
I -- REGISTRANT INFORMATION
Adamis
Pharmaceuticals Corporation
|
Full Name of Registrant
|
|
Former Name if
Applicable
|
11682
El Camino Real, Suite 300
|
Address of Principal
Executive Office (Street and Number)
|
San
Diego, CA 92130
|
City, State and
Zip Code
|
PART
II -- RULES 12b - 25(b) and (c)
|
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b - 25(b), the following should be completed. (Check box if appropriate.)
|
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated
without unreasonable effort expense;
|
|
☒
|
(b)
The subject annual report, semi-annual report, transition report on Form 10-Q, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or a portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or a portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
☐
|
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
State below in reasonable detail the reasons why Forms 10-K, 20-F,
11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period. (Attach
extra sheets if needed.)
Adamis Pharmaceuticals Corporation (the
“Registrant” or the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect
to its Quarterly Report on Form 10-Q for the three-month and six-month periods ended June 30, 2020 (the “Form
10-Q”). As previously reported, on June 18, 2020, the audit committee of the board of directors of the Company
dismissed the Company’s former independent registered public accounting firm and retained a new independent registered
public accounting firm. The Company requires additional time to gather information, and prepare, analyze and review certain
information relating to the presentation of financial information and relating to matters occurring during the period covered
by the Form 10-Q, and to complete its preparation and review of its financial statements and other disclosures in the Form
10-Q, which could not be completed by the date required without incurring unreasonable effort and expense. The Company
anticipates that it will file its Form 10-Q as soon as reasonably possible and within the 5-day grace period provided by Rule
12b-25 of the Securities Exchange Act of 1934, as amended.
PART
IV – OTHER INFORMATION
|
|
(1)
|
Name
and telephone number of person to contact in regard to this notification.
|
|
Robert O. Hopkins
|
(858) 997-2400
|
|
(Name)
|
(Area
Code and Telephone Number)
|
|
(2)
|
Have
all other periodic reports required under section 13 or 15(d) of the Securities Exchange
Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding
12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
|
☒
Yes ☐ No
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
|
☒
Yes ☐ No
For
the reasons stated above in Part III, the Company cannot reasonably estimate at this time the anticipated change to its results
of operations, but it expect the Company's revenue to decrease, and its net loss to increase, compared to the corresponding periods
for the last fiscal year ended June 30, 2019.
Adamis Pharmaceuticals Corporation
|
(Name
of Registrant as specified in its charter)
|
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: August 10, 2020
|
By:
|
/s/ ROBERT O. HOPKINS
|
|
|
Robert O. Hopkins
|
|
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024